MYC and pancreatic neoplasm: To investigate if the inhibition of the mevalonate pathway by c-Myc inhibitor could reduce mutp53 expression and mimic the effect induced by c-Myc inhibition, we used Lovastatin, an inhibitor of the mevalonate pathway, and found that it reduced both mutp53 expression level (Figure 4B) and pancreatic cancer cell viability (Figure 4C).